Dai Nghiem, MD
Transplant Surgery · Sacramento, CANPI 1285635672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,809 and has fallen 88.8% since, to $203 in 2025.
Across 80 payments — averaging $66.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$671
- AstraZeneca$470
- Lilly USA, LLC$461
- Gilead$459
- AbbVie$282
- Novo Nordisk$275
- plus $3K from 26 others
What the payments were for
- Travel & lodging$40%
- Food & beverage$5,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 13 | $671 |
| AstraZeneca | 4 | $470 |
| Lilly USA, LLC | 6 | $461 |
| Gilead | 8 | $459 |
| AbbVie | 4 | $282 |
| Novo Nordisk | 8 | $275 |
| Sanofi | 2 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $243 |
| Edwards Lifesciences | 1 | $161 |
| Phathom Pharmaceuticals, Inc. | 5 | $157 |
| Boehringer Ingelheim | 2 | $151 |
| Xeris Pharmaceuticals, Inc. | 2 | $151 |
| Johnson & Johnson | 1 | $150 |
| Dexcom, Inc. | 2 | $129 |
| Pfizer | 1 | $129 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Optinose US, Inc. | 1 | $125 |
| Arcutis Biotherapeutics, Inc. | 2 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $119 |
| Antares Pharma, Inc. | 1 | $117 |
| Cequr Corporation | 1 | $90 |
| Urovant Sciences Inc | 1 | $81 |
| Merck | 2 | $32 |
| Shionogi Inc | 1 | $26 |
| Zimmer Biomet | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,331 in reported general payments places this provider in the 70th percentile of 56 transplant surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 55 | $28,628 |
| JardianceEmpagliflozin | 22 | $27,331 |
| FarxigaDapagliflozin Propanediol | 25 | $23,784 |
| JanuviaSitagliptin Phosphate | 28 | $18,449 |
| VascepaIcosapent Ethyl | 21 | $9,812 |
| LinzessLinaclotide | 17 | $9,388 |
| RybelsusSemaglutide | 11 | $9,144 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $3,628 |
| Tenofovir Disoproxil Fumarate | 14 | $1,941 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,449 |
| Lidocaine | 12 | $1,113 |
| Omega-3 Acid Ethyl Esters | 12 | $1,060 |
| Atorvastatin Calcium | 127 | $786 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $775 |
| Tamsulosin Hcl | 80 | $768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $151 | $27,33122 claims |
| AstraZenecaFarxiga | $470 | $23,78425 claims |
| MerckJanuvia | $32 | $18,44928 claims |
| AbbVieLinzess | $282 | $9,38817 claims |
| Novo NordiskRybelsus | $275 | $9,14411 claims |
| GSKShingrix | $19 | $3,62818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 56 transplant surgery providers in California.
Other transplant surgery in Sacramento
- Junichiro SageshimaSacramento$3K
- Naeem GoussousSacramento$3K
- Neal MineyevSacramento$2K
- Sophoclis AlexopoulosSacramento$1K
- Yvonne KellySacramento$628
- Richard PerezSacramento$182
- Elizabeth SquiersHalf Moon Bay$1.3M
- Myron TongPasadena$99K
- Robert RedfieldOrange$65K
- Yuri GenykLos Angeles$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.